Net Income for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current net income (TTM) is $3.95B USD. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingNet IncomeSwitch metric
TTM (last 4 quarters)
$3.95B
YoY change
-838.1%
5Y CAGR
+7.8%
Peak year (2025)
$3.95B
Cumulative net income
$13.59B
Net Income history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Net Income history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Net Income | YoY |
|---|---|---|---|---|
| 2025 | $3.95B | -838.1% | ||
| 2024 | -$535.60M | -114.8% | ||
| 2023 | $3.62B | +9.0% | ||
| 2022 | $3.32B | +41.8% | ||
| 2021 | $2.34B | -13.6% | ||
| 2020 | $2.71B | +130.4% | ||
| 2019 | $1.18B | -43.9% | ||
| 2018 | $2.10B | +695.8% | ||
| 2017 | $263.48M | -335.1% | ||
| 2016 | -$112.05M | -79.9% | ||
| 2015 | -$558.12M | -24.4% | ||
| 2014 | -$738.55M | +66.0% | ||
| 2013 | -$445.03M | +315.8% | ||
| 2012 | -$107.03M | -461.9% | ||
| 2011 | $29.57M | -103.9% | ||
| 2010 | -$754.63M | +17.6% | ||
| 2009 | -$641.58M | +39.5% | ||
| 2008 | -$459.85M | +17.5% | ||
| 2007 | -$391.28M | +89.1% | ||
| 2006 | -$206.89M | +1.7% | ||
| 2005 | -$203.42M | +22.4% | ||
| 2004 | -$166.25M | -15.5% | ||
| 2003 | -$196.77M | +81.2% | ||
| 2002 | -$108.62M | +64.0% | ||
| 2001 | -$66.23M | +67.0% | ||
| 2000 | -$39.66M | -3.3% | ||
| 1999 | -$41.00M | +23.9% | ||
| 1998 | -$33.10M | +67.2% | ||
| 1997 | -$19.80M | -50.5% | ||
| 1996 | -$40.00M | +86.0% | ||
| 1995 | -$21.50M | +22.2% | ||
| 1994 | -$17.60M | -980.0% | ||
| 1993 | $2.00M | -123.5% | ||
| 1992 | -$8.50M | +66.7% | ||
| 1991 | -$5.10M | +18.6% | ||
| 1990 | -$4.30M | — |
Net Income values are taken from Vertex Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual net income for Vertex Pharmaceuticals (VRTX) came in at $3.95B – plunged 838.1% year-over-year.
Vertex Pharmaceuticals net income compound annual growth for the 2020–2025 (5 years) window is +7.8%, with the latest reading among the more recent periods of the dataset.
2025 marks the peak net income at $3.95B, with the historical low of -$754.63M recorded in 2010.
Vertex Pharmaceuticals (VRTX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $15.15B.
Vertex Pharmaceuticals Net Income by Year
Vertex Pharmaceuticals Net Income 2025: $3.95B
Vertex Pharmaceuticals net income in 2025 was $3.95B, plunged 838.1% below 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Net Income 2024: -$535.60M
Vertex Pharmaceuticals net income in 2024 was -$535.60M, plunged 114.8% below 2023.
Vertex Pharmaceuticals Net Income 2023: $3.62B
Vertex Pharmaceuticals net income in 2023 was $3.62B, grew 9.0% from 2022.
Vertex Pharmaceuticals Net Income 2022: $3.32B
Vertex Pharmaceuticals net income in 2022 was $3.32B, surged 41.8% from 2021.
Vertex Pharmaceuticals Net Income 2021: $2.34B
Vertex Pharmaceuticals net income in 2021 was $2.34B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Net Income
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest net income.
| Company | Net Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $102.43B | Healthcare |
| Johnson & Johnson (JNJ) | $26.80B | Healthcare |
| Eli Lilly and Company (LLY) | $20.64B | Healthcare |
| Merck & Co., Inc. (MRK) | $18.25B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $12.06B | Healthcare |
| AstraZeneca PLC (AZN) | $10.26B | Healthcare |
| Amgen Inc. (AMGN) | $7.71B | Healthcare |
| AbbVie Inc. (ABBV) | $4.23B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's net income?
- Latest reported net income for Vertex Pharmaceuticals (VRTX) is $3.95B (period ending December 31, 2025).
How has Vertex Pharmaceuticals net income changed year-over-year?
- Vertex Pharmaceuticals (VRTX) net income changed -838.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals net income?
- Vertex Pharmaceuticals (VRTX) net income compound annual growth rate is +7.8% over the most recent 5 years available.
When did Vertex Pharmaceuticals net income hit its highest annual value?
- Vertex Pharmaceuticals net income reached its highest annual value of $3.95B in 2025.
What was Vertex Pharmaceuticals net income in 2024?
- Vertex Pharmaceuticals (VRTX) net income in 2024 was -$535.60M.
What was Vertex Pharmaceuticals net income in 2025?
- Vertex Pharmaceuticals (VRTX) net income in 2025 was $3.95B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.